Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Enobia Pharma logo — company profile

Enobia Pharma

Founded 1997 Canada Montreal, Canada 8 employees Series Unknown Total: $160.65M Biotechnology, Health Care

General Information

Company Name Enobia Pharma
Founded Year 1997
Location Canada Montreal, Canada +2
Employees 8
Industries Biotechnology, Health Care
Funding Stage Series Unknown
Social

Get notified when Enobia Pharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Enobia Pharma

Enobia Pharma is a Canadian biotechnology company founded in 1997, dedicated to developing therapies for serious genetic bone disorders with no approved treatments. Their lead product, ENB-0040, is a subcutaneous bone-targeted enzyme replacement therapy designed for the rare disease hyposphostasia. The company specializes in the industries of Biotechnology and Health Care. Enobia Pharma received a significant $40.00M in Venture Round investment on 08 August 2011. This substantial investment reflects both the potential for their innovative therapeutic approaches and the confidence of investors in their ability to address unmet medical needs within the field of genetic bone disorders.

Taxonomy: Enobia, genetic bone disorders, therapies, ENB-0040, enzyme replacement therapy, hyposphosphatasia, subcutaneous, rare disease, tissue non-specific alkaline phosphatase, drug development, biopharmaceuticals

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $40.00M - 08 Aug 2011
Venture Round $15.00M - 01 Apr 2011
Series C $50.00M 4
OrbiMed Lothian Partners
CTI Capital, Desjardins Venture Capital 		10 Aug 2009
Series B $40.10M 5
OrbiMed CTI Life Sciences Fund Lothian Partners
Fonds de solidarité FTQ, Desjardins Venture Capital 		01 Aug 2007
Series A $15.55M 1 T2C2 Capital 18 Jan 2005

Enobia Pharma Alternatives & Competitors

Enobia Pharma vs
RevBio, Inc.
RevBio, Inc. United States

Transforming Bone Repair

Grant
32 employees
Biotechnology, Health Care
Enobia Pharma vs
Osteo-Pharma BV
Osteo-Pharma BV

Osteo-Pharma BV develops novel medication and medical devices for orthopedic and dental applications...

2 employees
Biotechnology, Pharmaceutical
Enobia Pharma vs
Biomendex
Biomendex Finland

For freedom to operate, join the story.

Grant
15 employees
Biotechnology, Health Care

FAQ About Enobia Pharma

Enobia develops therapies to treat serious genetic bone disorders for which there are no approved treatments. Our lead product in development, ENB-0040 (human recombinant tissue non-specific alkaline phosphatase), is a subcutaneous bone-targeted enzyme replacement therapy for the rare disease hyposp...
Enobia Pharma was founded in 1997.
Enobia Pharma is headquartered in Montreal, Canada.
Enobia Pharma operates in the following industries: Biotechnology, Health Care.
Enobia Pharma has approximately 8 employees.
Enobia Pharma has completed 5 funding rounds, raising a total of $160.65M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Enobia Pharma include RevBio, Inc., Osteo-Pharma BV, Biomendex, Bone Therapeutics, Novosteo. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Enobia Pharma and RevBio, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Enobia Pharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy